The REVOLUTION Trial

Why This Trial

Pancreatic cancer is not only one of the deadliest tumor types, and it’s becoming more common. It is also complex, with a variety of cell types, pathways and processes which make it resistant to most single therapies. This means defeating it will require the right combination of treatments.

About the Study

REVOLUTION uses what’s called a platform trial design, which allows our researchers to be flexible in ways that streamline the complicated process of setting up a clinical trial. It allows researchers to test different therapies and approaches at the same time, and it gives them the option to expand the size of each arm if the evidence suggests they should.

REVOLUTION currently consists of two arms.

Cohort A will test a combination of standard-of-care chemotherapy, the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab. In addition to providing valuable information on the efficacy of the combination itself, this cohort builds on the findings from PRINCE that suggested chemotherapy and PD-1 treatment combined may improve survival.

Cohort B will investigate chemotherapy, ipilimumab and hydroxychloroquine (HCQ). HCQ is a drug designed to stop a process called autophagy, when cancer cells recycle their own materials to survive – a potentially key process in pancreatic cancer.

Where We’re At Now

The trial initially opened for enrollment in May 2021. Both Cohort A and Cohort B are currently enrolling patients.

Locations

• The University of Pennsylvania (lead site)
• Dana-Farber Cancer Institute
• Memorial Sloan Kettering Cancer Center
• Stanford Medicine
• University of California, Los Angeles
• University of California, San Francisco
• The University of Texas MD Anderson Cancer Center

Researchers

Lead

• Robert Vonderheide, MD, DPhil | University of Pennsylvania

Site Investigators

• George Fisher, MD, PhD | Stanford Medicine
• Andrew Ko, MD | University of California, San Francisco
• Mark O’Hara, MD | University of Pennsylvania
• Eileen O’Reilly, MD | Memorial Sloan Kettering Cancer Center
• Osama Rama, MD | Dana Farber Cancer Institute
• Zev Wainberg, MD | University of California, Los Angeles
• Robert Wolff, MD | The University of Texas MD Anderson Cancer Center

Partners

• 1440 Foundation
• Bristol Myers Squibb
• Cancer Research Institute
• Pancreatic Cancer Action Network

For more information on this trial (NCT04787991), visit www.clinicaltrials.gov.